Ironwood Pharmaceuticals (IRWD) Income towards Parent Company (2010 - 2026)

Ironwood Pharmaceuticals has reported Income towards Parent Company for 17 years, with the latest figure at $40.8 million in Q1 2026.

• Quarterly Income towards Parent Company rose 209.06% year-over-year to $40.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.0 million (down 149.05% YoY) and the FY2025 annual result came in at -$137.1 million, down 189.39% from the prior year.
• Income towards Parent Company rose to $40.8 million in Q1 2026 per IRWD's latest filing, from -$163.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $154.8 million in Q4 2024 and troughed at -$1.1 billion in Q2 2023.
• A 5-year average of -$50.9 million and a median of $23.6 million in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company tumbled 3038.3% in 2023, then jumped 2844.07% in 2025.
• Over 5 years, Income towards Parent Company stood at $126.5 million in 2022, then plunged by 215.0% to -$145.5 million in 2023, then jumped by 206.4% to $154.8 million in 2024, then plunged by 205.57% to -$163.4 million in 2025, then surged by 124.95% to $40.8 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered $40.8 million, -$163.4 million, and $40.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.